Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0004153 (atherosclerosis)
 77,401 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Electrocardiographic and cardiovascular responses during maximal exercise were evaluated in 103 normal children and in 82 children with familial hyperlipoproteinemia. The normal and hyperlipidemic children were comparable in regards to age, weight--height index, resting and exercise blood pressures, and maximal working capacity indices. The cohort of 82 hyperlipidemic children included 61 children (29 boys and 32 girls) with well defined "monogenic" familial hyperlipoproteinemia. Segmental ST depression on the exercise electrocardiogram occurred in 8 of these 29 boys (27.6%) as compared to 4 of 55 normal boys (7.3%), P less than 0.025 and in 6 of the 32 girls (19%) as compared to 7 of 48 normal girls (14.6%), P greater than 0.1. Segmental ST depression was present in 14 of 61 (23%) children with "monogenic" hyperlipoproteinemia, as compared to 11 of 103 (10.75%) normal (x2 = 4.47, P less than 0.05). An assessment of the clinical significance of an abnormal exercise electrocardiogram in male children with "monogenic" hyperlipoproteinemia must await the following: (1) two to four decades of observation and study of the development of morbid or mortal coronary disease, or (2) the future development of improved invasive or noninvasive techniques for the early detection of covert coronary occlusive disease. Currently, maximal exercise electrocardiography cannot be contemplated as a useful indicator of eventual premature coronary artery disease in asymptomatic hyperlipidemic children.
Atherosclerosis 1976 Oct
PMID:Maximal exercise stress testing in normal and hyperlipidemic children. 18 80

The authors review the results of the clinical use of lovastatin in 150 patients with associated coronary heart disease and coronary atherosclerosis (according to coronarography). All the patients suffered from primary non-familial hyperlipoproteinemia (of the IIa and IIb types) and were entered into the placebo-controlled studies of the effectiveness of lovastatin. After 3 months of the treatment there was a decrease in the levels of total cholesterol (by 36%) (p less than 0.001); the content of cholesterol LDLP dropped by 48% (p less than 0.001), and that of triglycerides by 19% (p less than 0.01), while the level of cholesterol HDLP rose. Side effects were recorded in an insignificant number of cases. Therefore, lovastatin is a highly effective and well tolerable drug for the treatment of patients with coronary heart disease and hyperlipoproteinemia.
 ...
PMID:[The effect of lovastatin therapy on the dynamics of the clinical state of patients with ischemic heart disease and hyperlipoproteinemia]. 227 59

Twenty of approximately 1000 patients attending the arteriosclerosis clinic at MIT during a 13 year period were treated simultaneously with aspirin and warfarin for symptomatic atherosclerotic (19) or rheumatic (1) heart or vascular disease. The average duration of therapy was 5.8 years. Thirteen patients suffered from familial hyperlipoproteinemia; only one patient had none of the major risk factors for arteriosclerosis. Refractory symptoms were related to the central nervous system in 13, peripheral vascular system in 5 and the heart in 2. All twenty patients became asymptomatic or showed marked clinical improvement on aspirin plus warfarin therapy. While on this therapy, complications, both thrombotic and hemorrhagic, occurred in 7 of the 20 patients (graft embolus in 1, and bleeding in 6; with one death as a result of intracranial bleeding) and sudden death, probably from acute myocardial ischemia, in a further 2 patients. We conclude that when alternative therapies are impossible or have proven to be of no avail in patients suffering from the complications of advanced atherosclerosis, the simultaneous administration of aspirin and warfarin may be a therapeutic alternative, although very close and careful followup of the patients' prothrombin times and clinical status is essential.
 ...
PMID:Simultaneous therapy with antiplatelet and anticoagulant drugs in symptomatic cardiovascular disease. 387 67

Fifty-five patients with ischemic heart disease, familial hyperlipoproteinemia type IIb and essential hypertension kept anti-atherosclerosis diet incorporating 20 g of ichthyenic oil for 4 weeks. The diet resulted in positive shifts in clinical manifestations, a fall in blood levels of total cholesterol, triglycerides, atherogenic coefficient. The clotting time and duration of hemorrhage proved longer. As to fatty acid composition of red cell and platelet membranes, proportion of omega-6 reduced, while the share of omega-3 rose. This may underly inhibited synthesis of PGE2 and PGF2 alpha noted in the examinees.
 ...
PMID:[Clinico-metabolic effects of fish oil in patients with ischemic heart disease, familial hyperlipoproteinemia and hypertension]. 804 6

During pregnancy physiological changes occur in the lipid metabolism due to changing hormonal conditions: the LDL cholesterol (LDL-C), triglycerides (TG) and lipoprotein(a) [Lp(a)] increase throughout pregnancy. Common lipoprotein disorders are associated in pregnancy with two major clinical disorders: severe hypertriglyceridemia (SHTG) is a potent risk factor for development of acute pancreatitis and elevated cholesterol due to greater concentrations of LDL and remnant lipoproteins and reduced levels of HDL promote atherosclerosis. The combination of homozygous Familial Hypercholesterolemia (HoFH) and pregnancy can be a fatal condition. Therapeutic plasma exchange (TPE) may be used for an urgent need of a fast and effective lowering of TG levels in order to prevent a severe pancreatitis episode or hypertriglyceridemia-induced complications during pregnancy. LDL apheresis can decrease LDL-C and prevent complications and can be considered in the treatment of pregnancies complicated by high LDL-C. These conditions are configured in patients with HeFH who were taking statins before pregnancy (selected cases), patients already receiving apheresis before pregnancy suffering from HoFH, patients suffering from hypertriglyceridemia due to familial hyperlipoproteinemia types I and V, and cases of hypertriglyceridemia secondary to diabetes.
...
PMID:Severe dyslipidemia in pregnancy: The role of therapeutic apheresis. 2662 68